Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 45,511

Document Document Title
WO/2018/161741A1
An APE1 inhibitor and an application thereof in preparing a drug for treating a tumor and a disease related to abnormal angiogenesis. The APE1 inhibitor has the structure shown in the following formula 1 and selectively inhibits a redox ...  
WO/2018/165541A1
Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).  
WO/2018/164240A1
The present invention provides a method for producing retinal pigment epithelial cells including the following steps: (1) a first step for culturing pluripotent stem cells for a period that does not exceed 30 days by using a medium conta...  
WO/2018/163151A1
An ophthalmic preparation useful for effective prevention or treatment of irritation to corneal or conjunctival epithelial cells as measured by Lissamine Green staining, in particular irritation due to causes other than infection, is dis...  
WO/2018/161798A1
The present invention belongs to the technical field of biomedicine. Provided are an improved anti-VEGFR-2 monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library was designed...  
WO/2018/162271A1
The invention relates to a topical composition for the treatment or amelioration of macular degeneration (MD), comprising one or more active ingredients, which are efficient for the treatment of MD by intraocular injection, or a pharmace...  
WO/2018/162860A1
The invention relates to compounds of formula (I): R1-NH-CH(R2)-P(=O)(OH)-CH2-C(R3)(R4)-CONH-C(R5)(R6)-COOR7, where R1 to R7 are as defined in the claims, for use of same in the treatment and/or prevention of ocular inflammation, and mor...  
WO/2018/164113A1
A model closely resembling human high myopia can be constructed by fitting a juvenile mouse with a minus lens capable of angle and width adjustment in correspondence to the growth of the mouse, and with a protector. Analysis with this mo...  
WO/2018/162846A1
The present invention relates to the prevention of diseases involving reactive oxygen species (ROS) of mitochondrial origin. More specifically, the invention relates to the use of an inhibitor of the production of mitochondrial ROS, in p...  
WO/2018/159700A1
The present invention establishes a technology for stably formulating an isoquinoline-6-amino derivative as an ophthalmic agent or the like. Provided is a medicinal preparation that is obtained by housing, in a package capable of blockin...  
WO/2018/159702A1
The present invention establishes a technology for stably formulating an isoquinoline-6-amino derivative as an ophthalmic agent or the like. Provided is a medicinal preparation that is obtained by housing, in a polyester-based resin cont...  
WO/2018/159701A1
The present invention establishes a technology for stably formulating an isoquinoline-6-amino derivative as an ophthalmic agent or the like. Provided is a medicinal preparation that is produced by housing, in a polyolefin-based resin con...  
WO/2018/158256A2
The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula (I), wherein - n = 0 or 1, - R...  
WO/2018/160849A1
Compositions and methods are provided for treating Leber congenital amaurosis (LCA) in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encodin...  
WO/2018/157730A1
The present invention relates to a urea-substituted aromatic ring-linked dioxane-quinazoline compound of formula (1) and a urea-substituted aromatic ring-linked dioxane-quinoline, or a pharmaceutically acceptable salt thereof or a hydrat...  
WO/2018/158681A1
The present invention relates to an ophthalmic composition comprising cobalamin, taurine and at least one tear substitute for use in the regeneration of corneal nerve fibres in subjects who have undergone a keratoplasty operation.  
WO/2018/161035A1
The present, disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate an...  
WO/2018/156593A1
Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s...  
WO/2018/154413A1
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with COL7Alwhether ex vivo or in vivo. For example, the present disclosure provides materials and methods fo...  
WO/2018/157151A1
Provided herein are methods, formulations, and compositions related to omega-3 fatty acids or esters thereof and maqui berry extract. Methods, formulations, and compositions as described herein provide for treatment of ocular diseases or...  
WO/2018/156501A1
This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.  
WO/2018/156596A1
The various examples presented herein are directed to an oil composition comprising at least one carotenoid in an amount greater than 50 mg/kg by weight of the oil composition; a docosahexaenoic acid (DHA) content greater than about 25% ...  
WO/2018/154440A1
Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropi...  
WO/2018/151239A1
The present invention addresses the problem of providing an acid-sensing ion channel inhibitor which is orally administrable. The solution of the present invention is a compound represented by formula (I) or a pharmaceutically acceptable...  
WO/2018/149426A1
A pharmaceutical preparation comprising molecular hydrogen H2 with increased anti-oxidative effect for the prevention and treatment of inflammatory and degenerative diseases.  
WO/2018/146171A1
The present invention relates to the treatment of mast cell activation diseases (MCAD). The present invention is based on the discovery that aminoquinoline compound (such) can improve clinical symptoms present in several MCAD patients. I...  
WO/2018/147409A1
The present application provides an aqueous composition for eye drops and nasal drops, which contains levocetirizine or a salt thereof as an active ingredient. One aspect of the present application contains levocetirizine or a salt there...  
WO/2018/148333A1
Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be ...  
WO/2018/144749A1
The instant disclosure provides methods and compositions related to discovery of a long-acting FGF21 as a therapeutic target for treatment or prevention of neovascular eye diseases or disorders that are characterized by angiogenesis, or ...  
WO/2018/141908A1
The present invention relates to a composition comprising a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, wherein said composition is sterile and wherein said composition comprises at...  
WO/2018/141922A1
The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject ...  
WO/2018/144786A1
A method of preventing post-operative endophthalmitis involves injecting an antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination...  
WO/2018/144742A1
Described herein are methods and compositions featuring a first compound that is a linear peptidic NPR-B agonist and a second compound that is a prostaglandin agonist or a β-adrenergic antagonist, which are useful in the treatment and/o...  
WO/2018/139599A1
Disclosed are: a compound represented by general formula (I), a pharmaceutically acceptable salt thereof or a solvate of the same; a medicinal composition comprising the same; use of the same for preventing or treating infectious disease...  
WO/2018/137683A1
Disclosed are a lanosterol prodrug compound, a pharmaceutically acceptable salt and an isomer thereof, and a pharmaceutical composition comprising the lanosterol prodrug compound and the use thereof in the preparation of a drug for treat...  
WO/2018/140611A1
Provided herein are methods and compositions for the treatment of diseases associated with angiogenesis and neovascularization. In one aspect, the invention relates to a method for treating a condition in an eye of a patient in need ther...  
WO/2018/138621A1
The present invention provides a stable, ophthalmic aqueous composition for topical administration comprising acetazolamide and an aqueous liquid capable of forming a pharmaceutically acceptable gel in situ when applied topically to a pa...  
WO/2018/138292A1
The present invention provides polypeptides having protease activity for use in the treatment or prevention of otitis in a subject. For example, the polypeptide may be used to treat otitis caused by a microbial infection. In particular, ...  
WO/2018/139991A1
The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age- related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing...  
WO/2018/134464A1
The invention relates to adenosine A3 receptor modulators of formula (I) and to a method for preparing said compounds. Other aspects of the present invention are pharmaceutical compositions comprising an effective quantity of said compou...  
WO/2018/133618A1
The present invention provides a use of chlorogenic acid in the preparation of a drug for treating and/or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatm...  
WO/2018/134738A1
The present invention relates to nutraceutical or pharmaceutical compositions based on combination of cyanidin-3-O-glucoside and verbascoside, or extracts of plant origin enriched in the two active ingredients, with a protective action o...  
WO/2018/136605A1
Disclosed herein are compositions comprising a first compound that is N- acetylcysteine or a salt thereof, optionally a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct; and a coating lay...  
WO/2018/133139A1
Application of paeoniflorin-6'-O-benzene sulfonate in a medicine for treating Sjögren's syndrome, the molecular formula of the paeoniflorin-6'-O-benzene sulfonate being C 29H 32O 13S.  
WO/2018/131491A1
The present invention provides a method for producing a corneal epithelial cell mass for use in the production of a corneal epithelial cell sheet for transplantation use, said method comprising the steps of: (1) preparing a cell mass con...  
WO/2018/126673A1
An application of albiflorin or a pharmaceutically acceptable salt thereof as an IDO inhibitor; albiflorin or a pharmaceutically acceptable salt thereof serving as an IDO inhibitor can be used for preparing a drug, food, health product, ...  
WO/2018/127830A1
The present invention relates to a composition which comprises peptides derived from S- Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, wh...  
WO/2018/126306A1
The present invention describes a pharmaceutical composition of biologically active peptides, associated with a controlled-release system using cyclodextrins or derivatives thereof, liposomes and biodegradable polymers and/or mixtures of...  
WO/2018/126522A1
An injectable intraocular sustained-release antiviral drug and a manufacturing method and application thereof. The antiviral drug is an insoluble phosphonoformate salt microcrystal. The insoluble phosphonoformate salt is a multivalent me...  
WO/2018/123918A1
Provided is a compound or a salt thereof, represented by the formula shown, which has a RORγt inhibitory effect and is useful as a preventive or therapeutic agent for autoimmune diseases, allergies, and the like.  

Matches 1 - 50 out of 45,511